abbvie glp-1 plans to build out its presence in obesity market abbvie glp-1 receptor agonist weight

These updated warnings include further advice for patients using oral contraceptives: Patients taking tirzepatide are advised to switch to a non-oral contraceptive or add a barrier method of contraception for 4 weeks after first taking the medicine and for 4 weeks after each increase in the dose

Exercise Performance: Enhances exercise recovery and supports better performance by boosting cellular efficiency

Similarities between tumor stroma generation and wound healing

Patients with diabetes should follow their individualised monitoring plan and report any concerning trends to their healthcare team

Apnimed anticipates submitting AD109 for FDA review in 2H2025